Oncology
Refine Search
Biotechnology
US biotech companies Dragonfly Therapeutics and Gilead Sciences have announced a collaboration designed to advance a number of Dragonfly's novel natural killer (NK) cell engager-based immunotherapies for oncology and inflammation indications. 3 May 2022
Biotechnology
US biotech Ikena Oncology and the Vall d’Hebron Institute of Oncology (VHIO) yesterday announced an alliance to enable generation and exploration of tumor and biomarker-specific data derived from specific patient populations. 3 May 2022
Pharmaceutical
Chinese biotech Hutchmed on Monday announced that the US Food and Drug Administration has issued a Complete Response Letter (CRL) regarding the New Drug Application (NDA) for surufatinib for the treatment of pancreatic (pNETs) and extra-pancreatic (non-pancreatic, epNETs) neuroendocrine tumors (NETs). 3 May 2022
Pharmaceutical
Soaring AstraZeneca sales beat estimates in 2022’s first quarter, but the company’s full-year guidance remains unchanged amid an uncertain Covid-19-product sales outlook and Chinese market challenges. 29 April 2022
Biotechnology
Outpacing analysts' expectations, New York–based cancer giant Bristol Myers Squibb has reported first quarter 2022 revenues of $11.6 billion, a 5% increase from the $11 billion achieved in the same period of 2021. 29 April 2022
Biotechnology
Gilead Sciences increased its quarterly revenue by 3% compared to the first quarter of 2021, the company announced in presenting its latest financial results. 29 April 2022
Pharmaceutical
Merck & Co has far exceeded estimates with its sales and earnings figures for the first quarter of 2022, sending shares up by 4% in Thursday morning’s trading. 28 April 2022
Pharmaceutical
French drugmaker Sanofi exceeded analyst estimates with its first-quarter 2022 earnings as its blockbuster immunology drug Dupixent (dupilumab) maintained its miraculous ascent. 28 April 2022
Pharmaceutical
British charity Cancer Research UK has launched a new project aimed at driving forward innovation in the development of oncology medicines. 28 April 2022
Biotechnology
Shares of US biotech giant Amgen were down almost 6% at $233.98 in pre-market trading today, following the company’s release of positive first-quarter 2022 results, but with a sting in the tail relating to back taxes, after markets closed on Wednesday. 28 April 2022
Pharmaceutical
The Breast Cancer Aotearoa Coalition (BCAC) says it is deeply disappointed by a report on cancer medicines released by New Zealand’s Cancer Control Agency, the Te Aho o Te Kahu. 28 April 2022
Pharmaceutical
The UK’s Competition and Markets Authority (CMA) said today that it has worked to ensure that pharmaceutical company Aspen’s commitments to reduce prices for life-saving cancer medicines can be enforced in the UK following its exit from the European Union. 27 April 2022
Biotechnology
Swiss pharma giant Novartis today announced positive top-line results from an interim analysis of the Phase III RATIONALE 306 study, which showed anti-PD-1 immune checkpoint inhibitor tislelizumab plus chemotherapy significantly improved overall survival (OS) compared to chemotherapy in patients with previously untreated unresectable, locally advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC), regardless of PD-L1 expression. 27 April 2022
Biotechnology
An antibody-drug conjugate (ADC) developed by British drugmaker AstraZeneca and its Japanese partner Daiichi Sankyo has been granted Breakthrough Therapy designation (BTD) in the USA. 27 April 2022
Biotechnology
The China National Medical Products Administration (NMPA) has recently granted breakthrough therapy (BTD) designation to China’s Innovent Biologic’s IBI310 in combination with Tyvyt (sintilimab) to treat patients with recurrent or metastatic cervical cancer. 27 April 2022
Biotechnology
Data and analytics company GlobalData has found that the UK has a thriving oncology-focused startup and venture capital (VC) scene compared to its European neighbors. 26 April 2022
Pharmaceutical
Swiss pharma major Novartis edged marginally higher in the stock market on Tuesday after announcing that its first quarter sales and profits had done the same. 26 April 2022
Biotechnology
US biotech Nkarta, which is developing engineered natural killer cell therapies to treat cancer, saw its shares rocket more than 140% to $18.72 by close of trading on Monday, after it announced positive preliminary Phase I data from independent dose finding studies of its two lead chimeric antigen receptor (CAR) natural killer (NK) cell therapy candidates, 26 April 2022
Pharmaceutical
Reporting its second mid-stage flop in as many years, executives at Gossamer Bio have vowed to quickly shift the focus onto more promising pipeline assets. 26 April 2022
Pharmaceutical
The Russian government will allocate additional 23 billion roubles ($305 million) for the procurements of high-priced imported drugs as part of 14 high-cost nosologies (VZN) state program, reports The Pharma Letter’s local correspondent. 25 April 2022
Biotechnology
Japanese drugmaker Takeda has launched Fruzaqla (fruquintinib) in its home country. 22 November 2024
Biotechnology
Chinese biopharma CStone Pharmaceuticals has announced a strategic commercial collaboration with Pharmalink Store, a prominent pharmaceutical company based in the United Arab Emirates (UAE). 22 November 2024
Biotechnology
Privately-held US biotech Alloy Therapeutics has announced a strategic collaboration and license agreement with Takeda Pharmaceutical. 21 November 2024
Pharmaceutical
Japanese drugmaker Eisai has announced that the amyotrophic lateral sclerosis (ALS) treatment Rozebalamin for Injection (mecobalamin) has been launched in Japan as a treatment for slowing progression of functional impairment in amyotrophic lateral sclerosis. 21 November 2024
Biotechnology
The US Food and Drug Administration (FDA) has granted accelerated approval of Ziihera (zanidatamab-hrii) 50mg/mL for injection for intravenous use, say the drug’s developer, Jazz Pharmaceuticals. 21 November 2024
Biotechnology
San Diego-based Kura Oncology and Japan’s Kyowa Kirin have entered into a global strategic collaboration to develop and commercialize ziftomenib. 21 November 2024
Pharmaceutical
Shanghai-based Leading Tac Pharmaceutical has announced the successful completion of a series A financing round, raising over 100 million yuan ($14 million). 21 November 2024
Biotechnology
US biotech major Amgen has announced that Dr Howard Chang will join the company as senior vice president of research, effective December 16, 2024. 21 November 2024
Biotechnology
Bioplatform company builder Flagship Pioneering has announced its companies Ampersand Biomedicines and Montai Therapeutics have entered into agreements to identify targeted molecules that could potentially be further developed as treatments for obesity and lung cancer. 20 November 2024
Pharmaceutical
Ascentage Pharma will see its investigational BCL-2 selective inhibitor, lisaftoclax, assessed under China’s Priority Review scheme. 20 November 2024
Biosimilars
Sweden-based Xbrane Biopharma and Intas Pharmaceuticals have announced an exclusive global licensing and co-development agreement for the former company’s Opdivo (nivolumab) biosimilar candidate. 20 November 2024
Biotechnology
A pair of industry veterans have teamed up to create Jupiter Bioventures, a San Francisco-based biotech venture foundry promised to build bold, science-driven therapeutics companies. 20 November 2024
Biotechnology
The UK’s health technology assessor the Institute for Health and Clinical Excellence (NICE) says that talks with the makers of Enhertu have ended without agreement, meaning guidance that does not recommend Enhertu for advanced breast cancer will remain unchanged. 20 November 2024
Biotechnology
German biotech CatalYm has followed up a groundbreaking 2023 with an impressive 2024. 19 November 2024
Biotechnology
US pharma giant Merck & Co today announced positive top-line results from the pivotal Phase III MK-3475A-D77 trial for its mega blockbuster drug Keytruda (pembrolizumab) in subcutaneous form. 19 November 2024
Biotechnology
Privately-held US biotech Georgiamune has announced the appointment of Mark Avagliano as chief business officer (CBO). 19 November 2024
Biotechnology
Germany’s Lindis Biotech, a specialist in multi-specific antibody platforms, has announced an exclusive licensing agreement with Pharmanovia, for the commercialization of Korjuny (catumaxomab). 19 November 2024
Biotechnology
Californian oncology-focused biotech Avenzo Therapeutics has announced a pair of important updates. 19 November 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze